Allarity Therapeutics Files 8-K on Material Agreement
Ticker: ALLR · Form: 8-K · Filed: Jan 25, 2024 · CIK: 1860657
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-action, regulatory-filing
TL;DR
**Allarity Therapeutics just filed an 8-K about a new material agreement; details pending but could be a game-changer.**
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on January 25, 2024, to report an "Entry into a Material Definitive Agreement" and "Financial Statements and Exhibits." This filing indicates a significant new agreement that could impact the company's financial position or operations. For investors, this matters because material agreements often involve new partnerships, financing, or strategic changes that can affect the stock's future value and risk profile.
Why It Matters
This filing signals a potentially significant business development for Allarity Therapeutics, which could influence its financial health and strategic direction. Investors should investigate the details of the material agreement to understand its implications for the company's future prospects.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement without disclosing its specifics, creating uncertainty about its potential positive or negative impact on the company.
Analyst Insight
A smart investor would monitor Allarity Therapeutics for subsequent filings or press releases that provide specific details about the "Material Definitive Agreement" to assess its potential impact on the company's valuation and future prospects before making any investment decisions.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — the registrant filing the 8-K
- Nasdaq Stock Market LLC (company) — the exchange where Allarity's common stock is registered
- January 25, 2024 (date) — date of earliest event reported and filing date
- $0.0001 (dollar_amount) — par value per share of Common Stock
Forward-Looking Statements
- Allarity Therapeutics will release further details about the 'Material Definitive Agreement' in a subsequent filing or press release. (Allarity Therapeutics, Inc.) — high confidence, target: 2024-02-25
- The 'Material Definitive Agreement' will involve a partnership or financing deal to support drug development. (Allarity Therapeutics, Inc.) — medium confidence, target: 2024-06-30
FAQ
What is the primary purpose of this 8-K filing by Allarity Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report an "Entry into a Material Definitive Agreement" and to include "Financial Statements and Exhibits," as indicated in the Item Information section of the filing dated January 25, 2024.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 25, 2024, which is also the date of the report.
What is the trading symbol and the exchange where Allarity Therapeutics, Inc.'s common stock is registered?
Allarity Therapeutics, Inc.'s common stock trades under the symbol ALLR and is registered on The Nasdaq Stock Market LLC.
What is the par value per share of Allarity Therapeutics, Inc.'s Common Stock?
The par value per share of Allarity Therapeutics, Inc.'s Common Stock is $0.0001 per share.
Is Allarity Therapeutics, Inc. considered an emerging growth company according to this filing?
The filing includes a checkbox section to indicate whether the registrant is an emerging growth company, but the box is not checked, implying it is not simultaneously satisfying the filing obligation under those provisions, and the question about emerging growth company status is left unanswered by a checkmark.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-01-25 17:24:53
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea192203-8k_allarity.htm (8-K) — 27KB
- ea192203ex10-1_allarity.htm (EX-10.1) — 17KB
- 0001213900-24-006554.txt ( ) — 218KB
- allr-20240125.xsd (EX-101.SCH) — 3KB
- allr-20240125_lab.xml (EX-101.LAB) — 33KB
- allr-20240125_pre.xml (EX-101.PRE) — 22KB
- ea192203-8k_allarity_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Amendment to Securities Purchase Agreement On January 25, 2024, Allarity Therapeutics, Inc., a Delaware corporation ("we," "our," or the "Company") and 3i, LP, a Delaware limited partnership (the "Purchaser"), executed an amendment (the "Amendment") to that certain Securities Purchase Agreement dated as of January 18, 2024 (the "Original Agreement"). The Amendment amends and restates Section 4.22 of the Original Agreement to clarify that Purchaser shall have demand registration rights at any time beginning 90 calendar days after the First Closing Date (as defined in the Original Agreement). A copy of the Original Agreement was filed as Exhibit 10.1 to our Current Report on Form 8-K previously filed with the Securities and Exchange Commission on January 19, 2024. The foregoing summary of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy which is filed herewith as Exhibit 10.1, which is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Exhibit Description 10.1 Amendment to Securities Purchase Agreement, dated as of January 25, 2024, by and between the Company and the Purchaser listed on the signature page attached thereto 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: January 25, 2024 By: /s/ Thomas Jensen Thomas Jensen Chief Executive Officer 2